Tarceva (erlotinib) in combination with gemcitabine is indicated for patients with advanced pancreatic cancer.
Tarceva Access Solutions provides coverage and reimbursement support, patient assistance and informational resources for both health care providers and their patients.
Tarceva in combination with gemcitabine is indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Information intended to help you manage the common side effects associated with Tarceva, particularly rash.
This site is intended for US residents only.
© 2008 Genentech USA, Inc. and OSI Pharmaceuticals, Inc. All rights reserved.
Tarceva®, its logo mark and 
are trademarks of OSI Pharmaceuticals, Inc.
Health Care ProfessionalsTarceva for Advanced Pancreatic Cancer |
Tarceva Access Solutions™ can help.
888-249-4918
